Other languages Rhythm Pharmaceuticals, Inc.

Equities

RYTM

US76243J1051

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-02 pm EDT			5-day change	1st Jan Change
40.98 ^USD	-1.09%		+7.42%	-10.85%

Apr. 30	Rhythm Pharmaceuticals, Inc. Announces Publication of Results from Phase 2 Study of Setmelanotide for the Treatment of Hypothalamic Obesity in the Lancet Diabetes & Endocrinology	CI
Apr. 18	Wells Fargo Trims Price Target on Rhythm Pharmaceuticals to $52 From $53, Maintains Overweight Rating	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Rhythm Pharmaceuticals, Inc. Announces Publication of Results from Phase 2 Study of Setmelanotide for the Treatment of Hypothalamic Obesity in the Lancet Diabetes & Endocrinology	Apr. 29
Rhythm Pharmaceuticals to Sell $150 Million in Series A Convertible Preferred Stock	Apr. 01
Rhythm Pharmaceuticals Doses First Patients in Phase 1 Trial of Potential Obesity Therapy	Mar. 25
Rhythm Pharmaceuticals Announces First Patient Dosed in Phase 1 Trial Evaluating RM-718, a Weekly MC4R-specific Agonist	Mar. 25
Rhythm Pharmaceuticals Insider Sold Shares Worth $735,600, According to a Recent SEC Filing	Mar. 22
Rhythm Pharmaceuticals Insider Sold Shares Worth $707,005, According to a Recent SEC Filing	Mar. 22
Perceptive Advisors Engages in Discussion with Rhythm Pharmaceuticals	Mar. 20
Rhythm Pharmaceuticals Insider Sold Shares Worth $608,498, According to a Recent SEC Filing	Mar. 20
Rhythm Pharmaceuticals Insider Sold Shares Worth $627,520, According to a Recent SEC Filing	Mar. 20
Rhythm Pharmaceuticals Insider Sold Shares Worth $608,498, According to a Recent SEC Filing	Mar. 20
Rhythm Pharmaceuticals Insider Sold Shares Worth $608,498, According to a Recent SEC Filing	Mar. 20
Rhythm Pharmaceuticals Insider Sold Shares Worth $608,498, According to a Recent SEC Filing	Mar. 20
Rhythm Pharmaceuticals Says Planning to Add More Japanese Patients to Phase 3 Hypothalamic Obesity Trial	Feb. 22
Rhythm Pharmaceuticals' Q4 Net Loss Narrows, Revenue Rises; Shares Down Pre-Bell	Feb. 22
Rhythm Pharmaceuticals, Inc. Announces Clinical Development Plan of Setmelanotide for Hypothalamic Obesity in Japan	Feb. 22
Rhythm Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 22
Rhythm Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 22
Rhythm Pharmaceuticals Announces Positive Reimbursement Decision in Italy for Imcivree® (Setmelanotide) for the Treatment of Obesity and Control of Hunger in Bardet-Biedl Syndrome	Feb. 07
LG Chem Enters Deal with Rhythm Pharmaceuticals to Sell Anti-Obesity Drug Rights	Jan. 04
Rhythm Pharmaceuticals Completes Patient Screening for Enrollment in Phase 3 Trial of Obesity Treatment	Jan. 04

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Rhythm Pharmaceuticals, Inc.

Equities

RYTM

US76243J1051

Other languages

Filters